Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Cash & Equivalents (2016 - 2025)

Firefly Neuroscience has reported Cash & Equivalents over the past 15 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $2.7 million for Q4 2025, up 51.77% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (up 51.77% YoY), and the annual figure for FY2025 was $2.7 million, up 51.77%.
  • Cash & Equivalents for Q4 2025 was $2.7 million at Firefly Neuroscience, down from $4.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for AIFF hit a ceiling of $9.5 million in Q1 2025 and a floor of $58000.0 in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $1.6 million (2024), compared with a mean of $2.5 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 98.82% in 2022 and later soared 3594.83% in 2023.
  • Firefly Neuroscience's Cash & Equivalents stood at $4.9 million in 2021, then tumbled by 98.82% to $58000.0 in 2022, then soared by 3594.83% to $2.1 million in 2023, then dropped by 15.54% to $1.8 million in 2024, then skyrocketed by 51.77% to $2.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $2.7 million (Q4 2025), $4.3 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.